EICHORCondition: Essential Thrombocythemia · Sponsor: Merck Sharp & Dohme LLC
The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated. Its primary objective is to compare bomedemstat to hydroxyurea with respect to durable clinicohematologic response (DCHR). The primary hypothesis is that bomedemstat is superior to hydroxyurea with respect to DCHR.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Palo Verde Cancer Specialists ( Site 0052) | Glendale, Arizona, United States | — |
| Los Angeles Cancer Network ( Site 0025) | Glendale, California, United States | — |
| Stanford Cancer Center ( Site 0024) | Palo Alto, California, United States | — |
| Exempla Lutheran Medical Center ( Site 0014) | Golden, Colorado, United States | — |
| Yale University School of Medicine ( Site 0051) | New Haven, Connecticut, United States | — |
| Parkview Research Center at Parkview Regional Medical Center ( Site 0006) | Fort Wayne, Indiana, United States | — |
| University of Michigan ( Site 0003) | Ann Arbor, Michigan, United States | — |
| Optum Care Cancer Center ( Site 0053) | Las Vegas, Nevada, United States | — |
| Levine Cancer Institute ( Site 0009) | Charlotte, North Carolina, United States | — |
| Duke University Health System (DUHS) ( Site 0012) | Durham, North Carolina, United States | — |
| Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 0013) | Winston-Salem, North Carolina, United States | — |
| The Ohio State University Wexner Medical Center ( Site 0028) | Columbus, Ohio, United States | — |
+ 159 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06456346